1414 Massachusetts Ave
Update
04/14/21
Arranta Bio to Build Out 130K SF at 1414 Mass Ave in Boxborough
Arranta Bio has announced a 130,000 SF additional buildout at their facility in Boxborough, MA to supplement their Watertown operations. The Boxborough site will be developed in phases, and work for the first two phases has begun; the total investment in Boxborough is expected to exceed $150 million and employ over 250 employees, with the first phases of construction underway and start-up of GMP suites expected early in 2022.
The facility will be designed with flexible GMP manufacturing in mind, ready to support future product development. Initial multi-client capacity will include up to multiple 2,000L scale single-use bioreactors for anaerobic bacteria or 1,000L scale single-use fermenters for aerobic bacteria and fully automated drug product manufacturing. Additionally, Arranta plans to add secondary packaging and labeling capabilities at the facility.
“We are excited by the recent clinical results that demonstrate the potential of microbiome therapies to positively impact patient outcomes in a broad range of diseases,” Mark Bamforth, Executive Chair and CEO of Arranta Bio, said. “This new facility demonstrates Arranta’s commitment to supporting the increasing maturity of the microbiome live biotherapeutic product sector by offering innovators best-in-class development and GMP manufacturing capabilities that support their programs from lab to market.”
“In discussions with leading microbiome innovators, we see strong interest in dedicated client capacity and new manufacturing capabilities to meet the commercial supply needs of this sector,” David Stevens, President and COO of Arranta Bio, said. “We are continuing to expand our organization, adding experience and skills to meet clients’ needs, and expect to have over 200 on our team by the end of 2021 and up to 500 employees once fully staffed.”
